ATXS PE Ratio & Valuation,Is ATXS Overvalued

ATXS Relative Valuation

ATXS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATXS is overvalued; if below, it's undervalued.

Historical Valuation

Astria Therapeutics Inc (ATXS) is now in the Fair zone, suggesting that its current forward PS ratio of 216.42 is considered Fairly compared with the five-year average of -3.85. The fair price of Astria Therapeutics Inc (ATXS) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：12.98

Fair

-5.76

-3.49

EV/EBITDA

Astria Therapeutics Inc. (ATXS) has a current EV/EBITDA of -3.49. The 5-year average EV/EBITDA is -1.87. The thresholds are as follows: Strongly Undervalued below -5.00, Undervalued between -5.00 and -3.43, Fairly Valued between -0.30 and -3.43, Overvalued between -0.30 and 1.27, and Strongly Overvalued above 1.27. The current Forward EV/EBITDA of -3.49 falls within the Undervalued range.

-4.18

EV/EBIT

Astria Therapeutics Inc. (ATXS) has a current EV/EBIT of -4.18. The 5-year average EV/EBIT is -2.19. The thresholds are as follows: Strongly Undervalued below -5.49, Undervalued between -5.49 and -3.84, Fairly Valued between -0.54 and -3.84, Overvalued between -0.54 and 1.11, and Strongly Overvalued above 1.11. The current Forward EV/EBIT of -4.18 falls within the Undervalued range.

216.42

Astria Therapeutics Inc. (ATXS) has a current PS of 216.42. The 5-year average PS is 11.66. The thresholds are as follows: Strongly Undervalued below -78.50, Undervalued between -78.50 and -33.42, Fairly Valued between 56.73 and -33.42, Overvalued between 56.73 and 101.81, and Strongly Overvalued above 101.81. The current Forward PS of 216.42 falls within the Strongly Overvalued range.

-6.61

P/OCF

Astria Therapeutics Inc. (ATXS) has a current P/OCF of -6.61. The 5-year average P/OCF is -3.22. The thresholds are as follows: Strongly Undervalued below -9.81, Undervalued between -9.81 and -6.52, Fairly Valued between 0.07 and -6.52, Overvalued between 0.07 and 3.36, and Strongly Overvalued above 3.36. The current Forward P/OCF of -6.61 falls within the Undervalued range.

-6.15

P/FCF

Astria Therapeutics Inc. (ATXS) has a current P/FCF of -6.15. The 5-year average P/FCF is -2.60. The thresholds are as follows: Strongly Undervalued below -8.96, Undervalued between -8.96 and -5.78, Fairly Valued between 0.58 and -5.78, Overvalued between 0.58 and 3.77, and Strongly Overvalued above 3.77. The current Forward P/FCF of -6.15 falls within the Undervalued range.

Astria Therapeutics Inc (ATXS) has a current Price-to-Book (P/B) ratio of 5.27. Compared to its 3-year average P/B ratio of 2.52 , the current P/B ratio is approximately 109.49% higher. Relative to its 5-year average P/B ratio of 4.20, the current P/B ratio is about 25.68% higher. Astria Therapeutics Inc (ATXS) has a Forward Free Cash Flow (FCF) yield of approximately -16.35%. Compared to its 3-year average FCF yield of -19.29%, the current FCF yield is approximately -15.21% lower. Relative to its 5-year average FCF yield of -29.07% , the current FCF yield is about -43.75% lower.

5.27

P/B

Median3y

2.52

Median5y

4.20

-16.35

FCF Yield

Median3y

-19.29

Median5y

-29.07

Competitors Valuation Multiple

The average P/S ratio for ATXS's competitors is 50.38, providing a benchmark for relative valuation. Astria Therapeutics Inc Corp (ATXS) exhibits a P/S ratio of 216.42, which is 329.59% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ATXS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATXS in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Astria Therapeutics Inc (ATXS) currently overvalued or undervalued?

What is Astria Therapeutics Inc (ATXS) fair value?

ATXS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Astria Therapeutics Inc (ATXS) is between to according to relative valuation methord.

How does ATXS's valuation metrics compare to the industry average?

What is the current P/B ratio for Astria Therapeutics Inc (ATXS) as of Jan 09 2026?

As of Jan 09 2026, Astria Therapeutics Inc (ATXS) has a P/B ratio of 5.27. This indicates that the market values ATXS at 5.27 times its book value.

What is the current FCF Yield for Astria Therapeutics Inc (ATXS) as of Jan 09 2026?

As of Jan 09 2026, Astria Therapeutics Inc (ATXS) has a FCF Yield of -16.35%. This means that for every dollar of Astria Therapeutics Inc’s market capitalization, the company generates -16.35 cents in free cash flow.

What is the current Forward P/E ratio for Astria Therapeutics Inc (ATXS) as of Jan 09 2026?

As of Jan 09 2026, Astria Therapeutics Inc (ATXS) has a Forward P/E ratio of -5.76. This means the market is willing to pay $-5.76 for every dollar of Astria Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Astria Therapeutics Inc (ATXS) as of Jan 09 2026?

As of Jan 09 2026, Astria Therapeutics Inc (ATXS) has a Forward P/S ratio of 216.42. This means the market is valuing ATXS at $216.42 for every dollar of expected revenue over the next 12 months.

ATXS Valuation